Joint Corp Amends Credit Facility, Enhances Capital Flexibility

The latest announcement is out from Joint ( (JYNT) ).

On May 1, 2026, The Joint Corp. amended its credit agreement with JPMorgan Chase, securing a waiver for a prior covenant violation, resetting its fixed charge coverage terms to permit stock repurchases and extending the maturity of its revolving credit facility to August 31, 2029. The company also highlighted that it retains an undrawn $20 million line of credit through August 2029, bolstering financial flexibility as it continues to return capital via share buybacks.

For the first quarter ended March 31, 2026, The Joint reported a 13% year-over-year revenue increase to $14.8 million, while consolidated net income rose 34% to $1.3 million and consolidated Adjusted EBITDA grew 22% to $3.5 million. Despite a 4.9% decline in system-wide sales and negative 4.2% comparable sales, improved cost discipline and refranchising benefits helped turn continuing operations from a prior-year loss to a $1.1 million profit.

The company continued to execute a sweeping refranchising strategy in March and April 2026, including an agreement to sell 45 company-owned or managed clinics in Southern California and a letter of intent to sell five clinics in Northern California. These transactions are expected to leave only three of 943 clinics company-operated, effectively transforming The Joint into a near pure-play franchisor and trimming approximately $300,000 of general and administrative expenses tied to corporate operations.

Clinic optimization and refranchising weighed on clinic count, which fell to 943 locations as of March 31, 2026, after three openings and 20 closures, while rights to three regional developer territories were repurchased to improve portfolio economics. Management said new B2B and direct-to-patient sales tests, alongside tighter cost controls, are designed to support top-line momentum and enhance margins in a softer same-store sales environment.

Cash flow from operating activities and free cash flow remained negative in the quarter but improved materially year over year, to $(1.5) million and $(1.7) million respectively, with unrestricted cash at $20.7 million at quarter-end. The Joint repurchased about 137,000 shares for $1.1 million at an average price of $8.35, leaving $4.5 million authorized for further buybacks, and reiterated its 2026 outlook for system-wide sales, comparable sales, Adjusted EBITDA and net new franchised clinic openings, while warning that additional closures could leave year-end clinic count below 2025 levels.

The most recent analyst rating on (JYNT) stock is a Hold with a $8.55 price target. To see the full list of analyst forecasts on Joint stock, see the JYNT Stock Forecast page.

Spark’s Take on JYNT Stock

According to Spark, TipRanks’ AI Analyst, JYNT is a Neutral.

The score is driven primarily by improving fundamentals and a cleaner balance sheet, but it is capped by the sharp 2025 cash-flow deterioration and still-inconsistent operating profitability. Earnings call guidance and refranchising progress add support, while technicals are neutral and valuation is stretched due to a high P/E without dividend support.

To see Spark’s full report on JYNT stock, click here.

More about Joint

The Joint Corp., based in Scottsdale, operates, manages and franchises chiropractic clinics nationwide under The Joint Chiropractic brand, positioning itself as the largest franchisor of chiropractic care in the U.S. The company uses a retail healthcare model that emphasizes convenient, affordable, insurance-free access to pain relief and wellness services, with more than 940 locations and over 14 million patient visits annually.

The brand has become a prominent player in the chiropractic industry, earning repeated recognition in major franchise rankings such as Franchise Times’ “Top 400” and Entrepreneur’s “Franchise 500.” Its model targets growing consumer demand for longevity, health span and non-invasive, whole‑body care, and is increasingly focused on a pure-play franchisor strategy to enhance scalability and profitability.

Average Trading Volume: 59,831

Technical Sentiment Signal: Strong Sell

Current Market Cap: $126M

See more insights into JYNT stock on TipRanks’ Stock Analysis page.